relapse rate
Showing 1 - 25 of >10,000
Patients With Schizophrenia Trial (Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG))
Not yet recruiting
- Patients With Schizophrenia
- Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
- (no location specified)
May 1, 2023
Asthma Trial in Paris (2: Intervention, 1: Control)
Completed
- Asthma
- 2: Intervention
- 1: Control
-
Paris, FranceService des Urgences, Hôpital Lariboisière
Mar 9, 2022
Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Pegylated interferon beta-1a
- Interferon Beta-1A Prefilled Syringe
-
Tehran, Iran, Islamic Republic ofSina Hospital
Feb 5, 2022
Steroid-Sensitive Nephrotic Syndrome Trial in Islamabad (Prednisolone)
Recruiting
- Steroid-Sensitive Nephrotic Syndrome
-
Islamabad, Capital, PakistanPakistan Institute of Medical Sciences
May 9, 2021
Mass Accumulation Rate asPredictive Biomarker in Multiple
Recruiting
- Multiple Myeloma in Relapse
-
Duarte, California
- +5 more
Jul 13, 2022
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications) Trial in St Petersburg
Recruiting
- Biochemical Relapse Free Survival
- Complications Rates (Erectile Dysfunction, GI, GU Complications)
- Stereotactic ablative radiotherapy
- High dose rate brachytherapy
-
St Petersburg, Russian FederationSergey Novikov
Apr 28, 2021
Biochemical Relapse Fo Malignant Tumor of Prostate Trial in Taipei (18F-FACBC PET/CT)
Recruiting
- Biochemical Relapse Fo Malignant Neoplasm of Prostate
- 18F-FACBC PET/CT
-
Taipei, TaiwanNational Taiwan University Hospital
Sep 8, 2021
Brain Metastases, Small Cell Lung Cancer Trial in Birmingham (NovoTTF-200A, Stereotactic Radiosurgery (SRS))
Terminated
- Brain Metastases
- Small Cell Lung Cancer
- NovoTTF-200A
- Stereotactic Radiosurgery (SRS)
-
Birmingham, AlabamaUniversity of Alabama at Birmingham (UAB), Hazelrig-Salter Radia
Feb 17, 2022
Neuromyelitis Optica Spectrum Disorder Trial in Isfahan (Azathioprine, Rituximab)
Completed
- Neuromyelitis Optica Spectrum Disorder
-
Isfahan, Iran, Islamic Republic ofKashani Hospital
Sep 29, 2020
Relapse Trial in Aarhus, Oslo (Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer)
Active, not recruiting
- Relapse
- Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer
-
Aarhus, Denmark
- +1 more
Dec 17, 2020
Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Umbilical Cord Blood
Recruiting
- Hematopoietic Malignancy
- +2 more
- Umbilical Cord Blood Transplantation
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow university
Nov 6, 2023
Alcohol Use Disorder Trial in Shenzhen (Very brief extinction, Clearly visible extinction, Very brief neutral extinction)
Not yet recruiting
- Alcohol Use Disorder
- Very brief extinction
- +2 more
-
Shenzhen, Guangdong, ChinaShenzhen Kangning Hospital
Jul 5, 2023
ADHD: Gaps Between Alcohol-dependence and Impact on Relapse
Unknown status
- Alcoholism
- Attention Deficit Disorder With Hyperactivity
- cognitive and psychiatric assessment
-
Lille, France
- +1 more
Aug 2, 2019
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in
Not yet recruiting
- Acute Myeloid Leukemia
- Genetic Predisposition to Disease
- Collection of blood sample of bone marrow (cohort 1)
- Collection of blood sample of bone marrow (cohort 2 and 3)
- (no location specified)
Mar 6, 2023
Smoking Cessation Trial in Hong Kong (Standard smoking cessation treatment, Personalised chat messaging, SMS text messaging)
Not yet recruiting
- Smoking Cessation
- Standard smoking cessation treatment
- +2 more
-
Hong Kong, Hong KongTung Wah Group of Hospitals Integrated Centre on Smoking Cessati
Dec 14, 2022
Acquired Hemophilia Trial in Tianjin (Daratumumab)
Recruiting
- Acquired Hemophilia
-
Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023
Relapse in Anorexia Nervosa. A Cohort Study
Recruiting
- Anorexia Nervosa
-
Garda, ItalyDepartment of Eating and Weight Disorders, Villa Garda Hospital
Apr 27, 2022
Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))
Withdrawn
- Prophylactic HQP1351 Therapy
- Third Generation TKI
- HQP1351( Olverembatinib dimesylate)
-
Guanzhou, ChinaDepartment of Hematology, Nanfang Hospital, Southern Medical Uni
Jan 16, 2023
Acute Myeloid Leukemia Trial (MCBC regimen, Bu/Cy regimen)
Not yet recruiting
- Acute Myeloid Leukemia
- MCBC regimen
- Bu/Cy regimen
- (no location specified)
Nov 13, 2023
Diffuse Large B Cell Lymphoma Trial in Philadelphia (Nivolumab, IV, 240 mg)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- Nivolumab, IV, 240 mg
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jan 3, 2023
Acute Promyelocytic Leukemia, Induction Therapy, Oral Trial in Beijing (Etoposide, Daunorubicin)
Recruiting
- Acute Promyelocytic Leukemia
- +2 more
-
Beijing, Beijing, ChinaPeking University Institute of Hematology
Apr 26, 2023
Active tDCS, Sham tDCS Trial in Brussels (tDCS)
Completed
- Active tDCS
- Sham tDCS
- tDCS
-
Brussels, BelgiumCHU-Brugmann
Jul 19, 2022
MDD, Recurrent, in Remission Trial (Negative ion therapy, Light therapy)
Not yet recruiting
- Major Depressive Disorder, Recurrent, in Remission
- Negative ion therapy
- Light therapy
- (no location specified)
Jul 19, 2022